Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulse photodynamic therapy with methyl aminolevulinate activated by a halogen lamp
2013-005438-39Phase 2Terminated
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Mar 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methyl aminolevulinate in actinic keratosis (AK), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Lesion clearance rate at 3 months. Started Mar 2014; status: terminated.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2013-005438-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005438-39.